Needham Reiterates Buy on TScan Therapeutics, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on TScan Therapeutics (NASDAQ:TCRX) and maintained a price target of $11.
August 12, 2024 | 5:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a Buy rating on TScan Therapeutics and maintained a price target of $11.
The reiteration of a Buy rating and the maintenance of a price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100